Evidence map›Paper›PMID 41803265›Full record

ArticleOncogene2026

Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD).

Koushik Guchhait, Hyeon-Seung Yoon, Hyun-Su An, Seungheon Shin, Hye Seung Nam, Francisco D Yanqui-Rivera, Samara M Oña, Miguel Á Mendez, Jong Yeon Hwang, Daeho Park and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Koushik Guchhait *Department of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Hyeon-Seung Yoon *Department of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Hyun-Su AnDepartment of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Seungheon ShinDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Hye Seung NamDepartment of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Francisco D Yanqui-RiveraDepartment of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Samara M OñaInstituto de Simulación Computacional (ISC-USFQ), Universidad San Francisco de Quito, Quito, Ecuador.
Miguel Á MendezInstituto de Simulación Computacional (ISC-USFQ), Universidad San Francisco de Quito, Quito, Ecuador.
Jong Yeon HwangTherapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology (KRICT), Daejeon, Korea.
Daeho ParkDepartment of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.ORCID http://orcid.org/0000-0002-2824-490X
Chul-Seung ParkDepartment of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Jee-Young HanDepartment of Pathology, Inha University Hospital, Incheon, Korea.
Doo Yong ChungDepartment of Urology, Inha University Hospital, Incheon, Korea.
Seokjae ParkDepartment of Brain and Cognitive Sciences, Neurometabolomics Research Center, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, Korea.ORCID http://orcid.org/0000-0002-3932-995X
Eun-Kyoung KimDepartment of Brain and Cognitive Sciences, Neurometabolomics Research Center, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, Korea.
Su-Geun YangDepartment of Biomedical Science, BK21 FOUR program in Biomedical Science and Engineering, Inha University College of Medicine, Incheon, Korea.
Steve K ChoDepartment of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea. scho@gist.ac.kr.ORCID http://orcid.org/0000-0001-8547-8430

Funding

Gwangju Institute of Science and Technology (GIST) Future-Leading Specialized Research Project, 2025Gwangju Institute of Science and Technology (GIST) GRI IIBR grantKorea Health Industry Development Institute (KHIDI) RS-2024-00512909National Research Foundation of Korea (NRF) 2017R1D1AB03028590National Research Foundation of Korea (NRF) RS-2023-00252326
6 · The paper itself

Abstract

Metastasis is the primary cause of mortality in advanced prostate cancer, and the emergence of resistance to androgen receptor (AR)-targeted therapies highlights the urgent need for alternative therapeutic strategies. Metabolic reprogramming has increasingly been recognized as a key driver of metastatic progression. In this study, we uncover a novel tumor-suppressive role for cereblon (CRBN), a substrate receptor of the CRL4

Indexed as

Adaptor Proteins, Signal TransducingPhosphogluconate DehydrogenaseProstatic NeoplasmsUbiquitin-Protein LigasesAnimalsCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansMaleMiceNeoplasm MetastasisUbiquitinationAdaptor Proteins, Signal TransducingCRBN protein, humanPhosphogluconate DehydrogenaseUbiquitin-Protein Ligases

Identifiers

PMID41803265
PMCPMC13033450

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.